DCE-MRI parameters have potential to predict response of locally advanced breast cancer patients to neoadjuvant chemotherapy and hyperthermia: a pilot study.
Int J Hyperthermia., 25(6):405-15 (2009)
Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.
J. Clin. Oncol., Dec;27(34):5838-47 (2009)
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.
J. Clin. Oncol., Mar;28(7):1124-30 (2010)
Hyperthermia combined with radiation therapy for superficial breast cancer and chest wall recurrence: a review of the randomised data.
Int J Hyperthermia., 26(7):612-7 (2010)
Hyperthermia for locally advanced breast cancer.
Int J Hyperthermia., 26(7):618-24 (2010)
Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes.
Breast Cancer Res., 13(3):R62 (2011)
Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors.
Mol. Cancer Ther., Aug;10(8):1367-74 (2011)
Safety of bevacizumab in patients with metastatic breast cancer.
Oncology., 80(5-6):314-25 (2011)
Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study.
J. Clin. Oncol., Jul;30(21):2585-92 (2012)
Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy.
AJR Am J Roentgenol., Nov;181(5):1275-82 (2003)
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.
J. Clin. Oncol., Apr;23(11):2502-12 (2005)
Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity.
Mol. Cancer Ther., Feb;5(2):356-61 (2006)
The effect of darbepoetin alfa on growth, oxygenation and radioresponsiveness of a breast adenocarcinoma.
Radiat. Res., Feb;165(2):192-201 (2006)
Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2.
J Transl Med., 5:42 (2007)
The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer.
Breast., Jan;17 Suppl 1:S15-24 (2008)
Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression.
J. Clin. Oncol., Jul;26(20):3324-30 (2008)
Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease.
Clin. Breast Cancer., Feb;8(1):50-64 (2008)
Are all aromatase inhibitors alike?
Breast Cancer Res. Treat., Dec;112 Suppl 1:35-43 (2008)
Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens.
Ann. Oncol., Jun;20(6):1026-31 (2009)
Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models.
Clin. Cancer Res., Nov;6(11):4359-64 (2000)